Novo Nordisk to Launch Cheaper Insulin Options in U.S.

Novo Nordisk announced that it will launch half-priced generic versions of its NovoLog and NovoLog Mix in the U.S. in January.

The lower cost generic of NovoLog (insulin aspart) will be sold at $144.68 per vial, and $279.41 for a pack of five FlexPens. The generic NovoLog Mix (insulin aspart mix 70/30) will cost $150.06 for a single vial, and $279.41 for a box of five FlexPens.

The company also announced that it will launch a $99 Cash Card program, enabling diabetes patients to purchase up to three vials or two packs of FlexPen/FlexTouch pens of any combination of Novo Nordisk insulins for a flat rate of $99.